Endo, Inc. (OTCQX: NDOI) revealed new insights from a post hoc data analysis of its Phase 3 clinical trial of XIAFLEX® ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...

For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...

CMS issued its Final Rule, establishing new Clinical Laboratory Improvement Amendments (CLIA) regulations (the Final ...

A stem cell therapy trial aimed at reducing neuroinflammation in patients with presymptomatic Alzheimer’s disease is underway ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...